It is reported that AstraZeneca, Pfizer and Novartis are all interested in purchasing Onyx pharmaceutical
-
Last Update: 2013-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
July 23, 2013 / bioun / -- Bloomberg 22 Daily said that according to people familiar with the situation, currently, Azn, Pfizer and Novartis are also preparing to bid for Onyx, while Amgen is still interested in acquiring Onyx Onyx has previously rejected a $10 billion offer from Amgen Amgen's offer is $120 per share in full cash, but Onyx's Board believes that Amgen's offer seriously undervalues the company's value and prospects According to analysts, the winner of the bidding will be kyrolis, the blood cancer drug of Onyx, whose sales are likely to soar nine times to $2.4 billion by 2019 Other pharmaceutical products include the anticancer drugs Nexavar (for liver and kidney cancer treatment) and stivarga (for gastric cancer treatment), which generated US $362 million in revenue in 2012, with 80% of sales coming from these two drugs.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
